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Effects of long-term magnesium 
supplementation on endothelial 
function and cardiometabolic risk 
markers: A randomized controlled 
trial in overweight/obese adults
Peter J. Joris1,2, Jogchum Plat1, Stephan J. L. Bakker3 & Ronald P. Mensink1,2
Long-term magnesium supplementation improves arterial stiffness, a cardiovascular disease risk 
marker. Effects on endothelial function may be another mechanism whereby increased magnesium 
intakes affect cardiovascular risk. Therefore, a 24-week, randomized, double-blind, placebo-controlled 
trial was performed to examine effects of magnesium supplementation on endothelial function and 
cardiometabolic risk markers. Fifty-two overweight and obese subjects (30 men and 22 women, age 
62 ± 6 years) were randomized to receive either three times daily magnesium (total dose: 350 mg) 
or placebo capsules. Endothelial function was assessed at the start and at the end of the study. 
Cardiometabolic risk markers were measured at baseline, after 12 weeks, and at week 24. Brachial 
artery flow-mediated vasodilation did not change following long-term magnesium supplementation 
(0.49 pp; 95% CI: −0.38 to 1.36 pp; P = 0.26). Changes in reactive hyperemia index, retinal microvascular 
caliber and plasma markers for microvascular endothelial function (sVCAM-1, sICAM-1 and sE-selectin) 
were also not different. In addition, no effects on serum lipids, plasma glucose, insulin sensitivity, 
and low-grade systemic inflammation were observed. In conclusion, a daily magnesium supplement 
of 350 mg for 24 weeks does not improve endothelial function and cardiometabolic risk markers in 
overweight and obese middle-aged and elderly adults.
Prospective cohort studies have not only found an inverse association between dietary magnesium intake and 
diabetes1, but also with cardiovascular disease (CVD) risk2, 3. However, the number of well-designed intervention 
trials to examine a potential causal role of magnesium intake in the prevention of CVD is very limited. Recently, 
we have reported that in overweight and obese adults magnesium supplementation for 24 weeks resulted in a 
clinically relevant reduction in arterial stiffness, suggesting a potential mechanism by which dietary magnesium 
affects cardiovascular health4. Effects on endothelial function and cardiometabolic risk markers, which were sec-
ondary outcomes of the study, were however not reported. Conventional cardiometabolic risk markers are known 
determinants of arterial stiffness5 and the vascular endothelium has also been suggested to play an important role 
in arterial stiffening6. Reported effects of magnesium intake on serum lipids, plasma glucose, insulin sensitivity 
and low-grade systemic inflammation are inconsistent7–11, while only a few well-controlled intervention studies 
have examined effects on endothelial function. These trials involved patients taking anti-hypertensive drugs or 
medication known to affect lipid or glucose metabolism12, 13, which may have masked effects of oral magnesium 
supplementation, and only used markers reflecting large artery (i.e. the brachial artery) endothelial function11–13.
Endothelial function can be assessed in different ways. Brachial artery flow-mediated vasodilation (FMD), 
an ultrasound measurement of a large peripheral muscular artery, is considered the current non-invasive gold 
standard technique14. The change in pulse wave amplitude in response to blood flow-induced increases in shear 
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stress is another functional marker of endothelial function, defined as the reactive hyperemia index (RHI). RHI 
reflects small artery reactivity15, while microvascular endothelial function can be assessed by measuring plasma 
markers that are synthesized by activation of the endothelium16. As these markers also relate to CVD risk17, 
effects on endothelial function of an increased magnesium intake were also assessed in our 24-week, randomized, 
double-blind, placebo-controlled intervention trial. The study involved overweight and obese middle-aged and 
elderly adults, because they are expected to have an impaired endothelial function18 and cardiometabolic distur-
bances at the start of the trial19, allowing for improvement by the intervention.
Results
Study subjects and compliance. The flow of participants through the study is shown in Supplemental 
Figure 1. A total of 51 subjects (29 men and 22 women) completed the trial. Baseline characteristics of these 
participants have been described before4. In brief, subjects were on average 62 ± 6 years old and their average 
BMI was 29.6 ± 2.8 kg/m2. Serum magnesium concentrations tended to increase in the magnesium compared 
with the placebo group by 0.02 mmol/L (95% CI: 0.00 to 0.04 mmol/L; P = 0.09) after 24 weeks, while twenty-four 
hour urinary magnesium excretion increased significantly by 2.01 mmol (95% CI: 1.22 to 2.93 mmol; P < 0.001) 
(Table 1). All subjects from the magnesium group had increased 24-hour urinary magnesium excretion con-
centrations at the end of the trial. This indicates that compliance of the subjects was excellent, as also evidenced 
from capsule counts. In fact, based on returned capsules, compliance ranged between 86% and 102%, and was on 
average >98% for the two treatment groups. No serious adverse events were reported in study diaries. Also, none 
of the participants has recorded in their study diaries any use of laxatives, which may contain magnesium oxide.
Vascular function markers. After 24 weeks of supplementation, changes in baseline brachial artery diame-
ters were not statistically different between the two treatment groups (Table 1). Also, FMD did not change (Fig. 1). 
In addition, no effects of long-term magnesium supplementation on the RHI were found. Finally, the central ret-
inal arteriolar equivalent (CRAE), central retinal venular equivalent (CRVE) and the retinal arteriolar-to-venular 
diameter ratio (AVR) did not change following long-term magnesium supplementation. Table 1 shows effects on 
plasma markers for microvascular endothelial function. No differences in soluble vascular cell adhesion molecule 
Magnesium Group Placebo Group Treatment Effect






























CRAE, μm 126 ± 17 124 ± 14 124 ± 15 128 ± 19 127 ± 20 125 ± 21 −1 (−4, 2) 1 (−1, 4)
CRVE, μm 223 ± 17 223 ± 15 222 ± 16 226 ± 19 225 ± 19 223 ± 21 1 (−2, 4) 1 (−1, 4)








sVCAM-1, ng/mL 746 ± 122 N/A 742 ± 127 725 ± 155 N/A 708 ± 99 N/A 21 (−23, 65)
sICAM-1, ng/mL 467 ± 75 N/A 479 ± 79 449 ± 72 N/A 425 ± 71 N/A 14 (−17, 45)
sE-selectin, ng/mL 9.6 ± 4.5 N/A 11.8 ± 4.4 9.3 ± 5.0 N/A 11.3 ± 5.7 N/A 0.3 (−1.7, 2.3)
Table 1. Magnesium concentrations and vascular function measurements at baseline, and after a 12-week 
and 24-week magnesium or placebo treatment in a randomized controlled trial (RCT) with overweight and 
obese middle-aged and elderly adults1. 1Magnesium group: n = 26; placebo group: n = 25. Mg: magnesium; 
FMD: flow-mediated vasodilation; CRAE: central retinal arteriolar equivalent; CRVE: central retinal venular 
equivalent; AVR: arteriolar-to-venular diameter ratio; sVCAM: soluble vascular cell adhesion molecule; sICAM: 
soluble intercellular adhesion molecule; sE-selectin: soluble endothelial selectin; N/A: not available. 2Values are 
means ± SDs. 3Values are mean changes (95% CI) obtained from a one-way ANCOVA with baseline value as 
covariate. Treatment effect: #P < 0.10, ##P < 0.001.
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(sVCAM)-1, soluble intercellular adhesion molecule (sICAM)-1 and soluble endothelial selectin (sE-selectin) 
concentrations were observed.
Cardiometabolic risk markers. Fasting total cholesterol, HDL-cholesterol, LDL-cholesterol, triacylg-
lycerol, non-esterified fatty acid (NEFA), glucose, insulin and HOMAIR did not differ after oral magnesium 
supplementation compared with the placebo treatment. The effects on plasma markers for low-grade systemic 
inflammation were also investigated. No effects were found on interleukin (IL)-6, IL-8, tumor necrosis factor 
(TNF)-α, C-reactive protein (CRP) and serum amyloid A (SAA) (Table 2). One man from the magnesium and 
four participants from the placebo group had CRP concentrations above 10 μg/mL on one (i.e. three CRP values 
at the start of the study and one at the end of the placebo treatment) or both occasions. Conclusions did not 
change when these participants were excluded form the statistical analyses (data not shown).
Discussion
In this randomized controlled trial (RCT) involving overweight and obese middle-aged and elderly adults, we 
found no significant effect on FMD, RHI, retinal microvascular caliber and plasma markers for microvascular 
endothelial function after 24 weeks of daily supplementation with 350 mg magnesium. Also, cardiometabolic risk 
markers did not change following magnesium supplementation.
The lack of effect on FMD is in agreement with several11, 12, but not all13, earlier randomized, double-blind, 
placebo-controlled intervention trials examining effects of magnesium supplementation. In a 6-month study in 
50 patients with stable coronary artery disease (CAD), a daily magnesium supplement of 365 mg increased FMD 
by 11.1 pp13. The observed improvement by Shechter et al.13 is very pronounced and related with an estimated 
decrease of approximately 90% in the long-term risk to develop CVD20. In retrospect, we had a statistical power 
of 80% (P < 0.05) to detect a true change in FMD of at least 1.30 pp. Thus, our study was certainly adequately 
powered to detect such a huge effect. Differences in subject characteristics may have contributed to these incon-
sistent results. CAD may be associated with magnesium depletion21 and a magnesium-deficient state was indeed 
found in 36 of the 50 CAD patients13. Also, study participants had low intracellular magnesium concentrations, 
as assessed in sublingual epithelial cells. In our intervention trial and others involving also apparently healthy 
individuals11 or patients on hemodialysis12, participants had baseline serum magnesium concentrations within 
normal ranges. This suggests that a very specific population was studied by Shechter13.
Baseline diameters of the brachial artery did not change in our study. Consequently, changes in brachial diam-
eters cannot explain our lack of effect on FMD. Also, no effects were found on the RHI. The RHI reflects small 
artery reactivity15, while FMD targets a large peripheral muscular artery14. To date, no other RCT has addressed 
the effect of magnesium supplementation on the RHI. Taken together, our study does not provide evidence that 
improvements in endothelial function have contributed to the beneficial effects on arterial stiffness associated 
with an increased magnesium intake for a 24-week experimental period, as reported previously4. As discussed4, 
long-term magnesium supplementation may primarily have an impact on the aorta and not on peripheral mus-
cular arteries, possibly as a result of improvements in the structural characteristics of large elastic arterial walls. In 
fact, longer-term use of magnesium in patients receiving hemodialysis significantly decreased common carotid 
artery intima-media thickness12, 22, which reflects structural changes of the arterial wall23, without any apparent 
effects on FMD12.
Magnesium supplementation did also not affect retinal microvascular caliber. To the best of our knowledge, 
no other RCTs have assessed the effects of magnesium on microvascular diameters. Finally, markers for micro-
vascular endothelial function were investigated in plasma, but no significant effects were observed for sVCAM-1, 
sICAM-1 and sE-selectin that are involved in the recruitment of leukocytes to the vascular wall24. In agreement, 
Chacko et al. observed that a daily magnesium supplement of 500 mg for four weeks did not change plasma con-
centrations of these markers in 14 otherwise healthy overweight individuals10.
Alternate possible mechanisms to explain the beneficial effects of oral magnesium supplementation on arterial 
stiffness in overweight and obese adults4 may relate to the postulated actions of magnesium on blood pressure and 
Figure 1. Individual changes in flow-mediated vasodilation. Effects of 24-week magnesium (black) and placebo 
supplementation (grey) on brachial artery flow-mediated vasodilation in overweight and obese middle-aged 
and elderly adults.
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other cardiometabolic risk markers25. However, we have already reported that blood pressure did not change4, 
while serum lipids and lipoproteins, plasma glucose, insulin sensitivity and plasma markers for low-grade sys-
temic inflammation were also comparable between the two treatment groups. A meta-analysis of nine RCTs 
involving patients with type II diabetes reported that magnesium supplementation (median daily dose: 360 mg) 
for 4 to 16 weeks increased HDL-cholesterol, but found no effects on total cholesterol, LDL-cholesterol and tria-
cylglycerol concentrations26. In healthy subjects, however, there is no evidence that an increased dietary magne-
sium intake improves the serum lipid profile9–11. A recent meta-analysis and systematic review of 21 randomized 
trials summarized the effects of magnesium supplements (range: 300 to 600 mg/day) on glucose, insulin and 
HOMAIR in both diabetic and non-diabetic individuals27. Study duration ranged from one to six months. In 
agreement, no effects were observed on fasting glucose and insulin. However, the HOMAIR significantly decreased 
suggesting that insulin sensitivity improved following oral magnesium supplementation. These effects were more 
pronounced in individuals with hypomagnesemia as compared with normomagnesemic subjects, but did not 
depend on the presence of diabetes. Adults who completed the present trial had serum magnesium concentra-
tions within normal range28, which may explain the lack of effect on the HOMAIR. Finally, no beneficial effects 
on pro-inflammatory cytokines were found. Similar conclusions were drawn in the very few RCTs that examined 
effects of magnesium supplementation on systemic inflammation in apparently healthy overweight adults10, 29.
Some limitations of the present trial warrant consideration. Our study was sufficiently powered to detect a 
change of 1.30 pp in FMD, while we estimated an effect of 0.49 pp (95% CI: −0.38 to 1.36 pp). Although the varia-
bility in our study was in line with findings of earlier studies30, we cannot exclude the possibility of false-negative 
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Table 2. Cardiometabolic risk measurements at baseline, and after a 12-week and 24-week magnesium or 
placebo treatment in a randomized controlled trial (RCT) with overweight and obese middle-aged and elderly 
adults1. 1Magnesium group: n = 26; placebo group: n = 25. NEFA: non-esterified fatty acid; IL: interleukin; 
TNF: tumor necrosis factor; CRP: C-reactive protein; SAA: serum amyloid A; N/A: not available. 2Values are 
means ± SDs or medians (25–75th percentile). 3For normally distributed variables, values are mean changes 
(95% CI) obtained from a one-way ANCOVA with baseline value as covariate. For non-normally distributed 
variables, variables are the median of the changes in respectively the magnesium and the placebo group. 
4Markers for low-grade systemic inflammation were tested by a Wilcoxon rank-sum test for non-normal 
distributed data. 5Magnesium group: n = 25; placebo group: n = 25. 6Magnesium group: n = 25; placebo group: 
n = 21. 7Magnesium group: n = 24; placebo group: n = 22.
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finding. However, other markers of endothelial function did also not change and we therefore do no consider it 
very likely that oral magnesium supplementation improves endothelial function. Studies on underlying mecha-
nisms are also needed, as the observed beneficial effects on large elastic arterial walls4 may relate to the postulated 
actions of magnesium on endothelial cells31. In fact, in vitro studies have shown that low extracellular magnesium 
induces the development of a pro-atherosclerotic phenotype of cultured endothelial cells32. Recent studies also 
suggest an important role of microRNAs on vascular function33 and the ability of endothelial cells to produce ath-
erogenic catecholamines34. Broadening our knowledge in these novel fields will contribute to our understanding 
of mechanisms by which an increased oral magnesium intake beneficially affects cardiovascular health outcomes.
In conclusion, the present results indicate that a magnesium intervention for 24 weeks does not improve 
endothelial function and cardiometabolic risk markers in overweight and obese men and postmenopausal 
women. It is therefore unlikely that effects on endothelial function have contributed to the beneficial effects on 
arterial stiffness.
Subjects and Methods
Subjects and study design. Overweight and slightly obese men and postmenopausal women with a mean 
age of 62 ± 6 years participated in a randomized, double-bind, placebo-controlled, parallel study with a 24-week 
experimental period, as described previously4. In brief, study subjects were allocated to receive either three times 
daily magnesium (total dose: 350 mg; Magnesium Citrate Complex [Mg 16%]) or placebo capsules containing 
starch (Amylum Solani). A total daily dose of 350 mg is considered the tolerable upper intake level (UL) of supple-
mental magnesium for adults35. All capsules were kindly provided by Laboratorium Medisan B.V. (Heerenveen, 
The Netherlands). The capsules were prepared in one batch. Participants maintained their habitual diet, physical 
activity levels and consumption of alcohol throughout the total study period. Inclusion and exclusion criteria have 
been described before4. Briefly, all volunteers were apparently healthy and did not receive proton pump inhibitors, 
anti-hypertensive medication or drugs known to affect lipid or glucose metabolism. Fifty-two overweight and 
obese study subjects were included. They had a BMI between 25 and 35 kg/m2; serum creatinine concentrations 
<116 μmol/L for men and <101 μmol/L for women; and no indications for treatment with cholesterol-lowering 
medications36. All study participants gave written informed consent before the start of the trial. The study was 
approved by the Ethics Committee of Maastricht University Medical Center, and registered on 8 September 2014 
at ClinicalTrials.gov as NCT02235805. The methods were performed in accordance with the described proce-
dures in the approved study protocol.
Blood sampling and analyses. Fasting blood samples were taken at the start of the study (days −3 and 
0), at week 12 (day 84), and at the end of the study (days 165 and 168) from a forearm vein by venipuncture. 
On the days preceding blood sampling, participants were requested not to consume alcohol or to perform any 
strenuous physical exercise. On the morning of blood sampling, subjects arrived after an overnight fast (no food 
or drink after 08.00 PM, except for water) at the Metabolic Research Unit Maastricht (MRUM) research facili-
ties by public transport or by car to the standardize measurements as much as possible. After blood sampling, 
NaF-containing vacutainer tubes (Becton, Dickinson and Company, Franklin Lanes, NY, USA) and EDTA-coated 
vacutainer tubes (Becton, Dickinson and Company) were immediately kept on ice and centrifuged within 30 min-
utes. To obtain plasma, plasma separator tubes were centrifuged at 1300× g for 15 minutes at 4 °C. Blood drawn 
in vacutainer serum tubes (Becton, Dickinson and Company) was first allowed to clot for at least 30 minutes at 
21 °C. To obtain serum, serum separator tubes were centrifuged at 1300× g for 15 minutes at 21 °C. Following 
centrifugation, plasma and serum samples were immediately portioned into aliquots and stored at −80 °C until 
analysis at the end of the trial.
Fasting glucose (Horiba ABX SAS, Montpellier, France) and NEFA concentrations (NEFA kit; WAKO 
Chemicals GmbH, Neuss, Germany) were measured in NaF-plasma. Fasting serum samples were analyzed for 
total cholesterol (Cobas 8000; Roche Diagnostics Systems, Hoffmann-La Roche Ltd., Mannheim, Germany), 
HDL-cholesterol (Cobas 8000; Roche Diagnostics Systems), triacylglycerol (Cobas 8000; Roche Diagnostics 
Systems), and insulin concentrations (RIA; Millipore, Billerica, MA, USA). LDL-cholesterol was calculated using 
the Friedewald formula37. The degree of insulin resistance was estimated by calculating the HOMAIR38. Fasting 
EDTA-plasma samples were analyzed for markers for low-grade systemic inflammation (IL-6, IL-8, TNF-α, 
CRP, SAA) and markers for microvascular endothelial function (sVCAM-1, sICAM-1, sE-selectin) by using a 
multi-array detection system based on electro-chemiluminescence technology (SECTOR Imager 2400; Meso 
Scale Discovery, Rockville, MD, USA)39.
Vascular function measurements. Measurements were performed at the start of the trial (day 0), at week 
12 (day 84), and at the end of the study (day 168) in a quiet and darkened room. The room was temperature 
controlled at 22 °C. After blood sampling and an acclimatization period of 30 minutes in the supine position, 
measurements were performed.
FMD was assessed using ultrasound echography (SONOS 5500; Hewlett-Packard [Philips], Andover, MA, 
USA) and recording of echo images on DVD40. After a 5-minute reference period, the pneumatic cuff placed 
around the participant's forearm was inflated to 250 mmHg for 5 minutes, causing distal hypoxia. Upon 
cuff-release reactive hyperemia ensued. The echo images were analyzed offline using a custom-written Matlab 
program (MyFMD V14.07; Prof. A.P. Hoeks, Department of Biomedical Engineering, Maastricht University 
Medical Center, Maastricht, The Netherlands). The FMD response was quantified as the maximal percent-
age change in post occlusion arterial diameter relative to baseline diameter. During FMD measurements, the 
Endo-PAT 2000 (Itamar Medical Ltd, Caesarea, Israel) was used to measure changes in pulse wave amplitude 
in response to reactive hyperemia. In brief, a pneumatic probe was placed on the index finger of both hands to 
record the peripheral arterial tone, according to instructions of the manufacturer. The RHI was quantified as the 
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post-to-pre occlusion peripheral arterial tone signal ratio in the occluded hand, normalized to values in the con-
trol hand and then further corrected for baseline vascular tone41. Finally, retinal vascular images were obtained to 
assess microvascular diameters in the eye. During this test, study participants were seated with their head resting 
on a chinrest, looking directly into the non-mydriatic retinal camera (Topcon TRC-NW-300; Topcon Co., Tokyo, 
Japan). The camera focused on the optic disc and photographed the retina. Images were digitized and analyzed 
to calculate the CRAE, CRVE, and retinal AVR with appropriate software (Generalized Dual-Bootstrap Iterative 
Closest Point [GDBP-ICP])42. In brief, the software automatically aligns the retinal images based on detected 
vascular centerlines by iteratively transforming the algorithm. At least two arteriolar and two venular retinal 
segments were measured and summarized by using the Parr-Hubbard formulas43. These segments had to be the 
same segments at each time point for an individual.
Statistical analyses. Study results are presented as means ± SDs, unless otherwise indicated. A per protocol 
analysis was performed. Differences in baseline values between the magnesium and placebo group were tested 
using an unpaired Student's t test. A one-way ANCOVA, using the baseline measurements of the outcome varia-
bles as covariates, was conducted to investigate differences in responses between magnesium and placebo treat-
ments. When residuals were not normally distributed as assessed with the Kolmogorov-Smirnov test, a Wilcoxon 
rank-sum was used. Changes were then calculated for each individual as the difference between the values at 
the end of the trial and at the start of the trial. A P < 0.05 was considered statistically significant. The study was 
powered on carotid-to-femoral pulse wave velocity, which was the primary outcome, but a retrospective power 
analysis showed that with 51 participants we had 80% power to detect a true change in FMD of at least 1.30 pp. 
For this power calculation, an alpha of 0.05 and observed within-subject variability in FMD of 1.64 pp were used. 
Analyses were performed using SPSS 23.0 (SPSS Incorporated, Chicago, IL, USA).
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